Generic drug price cuts could destabilize market, warn South Korean pharma firms

South Korea's government is implementing price reductions for generic drugs and medications whose patents have expired. This move aims to lower healthcare costs, but the pharmaceutical industry is raising concerns about potential market instability and the long-term impact on innovation.

Industry representatives state that the unpredictability of policy changes is a greater burden than the price cuts themselves. They argue that frequent adjustments to drug pricing create an uncertain business environment, making it difficult for companies to plan and invest.

This uncertainty, they contend, could lead to reduced investment in research and development (R&D) and hinder long-term strategic planning. Ultimately, the industry fears that these measures, while intended to save money, could paradoxically undermine the health insurance system's financial stability in the long run by stifling the development of new treatments.